HomeCompareIRCWF vs PFE

IRCWF vs PFE: Dividend Comparison 2026

IRCWF yields 14492.75% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IRCWF wins by $2154305968474146048.00M in total portfolio value
10 years
IRCWF
IRCWF
● Live price
14492.75%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2154305968474146048.00M
Annual income
$2,125,456,416,598,225,800,000,000.00
Full IRCWF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — IRCWF vs PFE

📍 IRCWF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIRCWFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IRCWF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IRCWF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IRCWF
Annual income on $10K today (after 15% tax)
$1,231,884.06/yr
After 10yr DRIP, annual income (after tax)
$1,806,637,954,108,492,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, IRCWF beats the other by $1,806,637,954,108,492,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IRCWF + PFE for your $10,000?

IRCWF: 50%PFE: 50%
100% PFE50/50100% IRCWF
Portfolio after 10yr
$1077152984237073024.00M
Annual income
$1,062,728,208,299,112,900,000,000.00/yr
Blended yield
98.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

IRCWF
No analyst data
Altman Z
-5.3
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IRCWF buys
0
PFE buys
0
No recent congressional trades found for IRCWF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIRCWFPFE
Forward yield14492.75%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$2154305968474146048.00M$51.1K
Annual income after 10y$2,125,456,416,598,225,800,000,000.00$27,210.54
Total dividends collected$2152396274958258432.00M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IRCWF vs PFE ($10,000, DRIP)

YearIRCWF PortfolioIRCWF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,459,975$1,449,275.36$9,161$701.38+$1.45MIRCWF
2$199,310,428$197,748,254.41$8,610$859.79+$199.30MIRCWF
3$25,443,037,058$25,229,774,899.52$8,366$1,081.25+$25443.03MIRCWF
4$3,037,238,126,713$3,010,014,077,061.22$8,483$1,405.66+$3037238.12MIRCWF
5$339,060,630,986,506$335,810,786,190,923.60$9,084$1,907.24+$339060630.98MIRCWF
6$35,398,380,947,675,984$35,035,586,072,520,424.00$10,418$2,732.78+$35398380947.67MIRCWF
7$3,456,345,235,755,821,000$3,418,468,968,141,808,000.00$13,007$4,193.56+$3456345235755.81MIRCWF
8$315,645,840,624,138,850,000$311,947,551,221,880,100,000.00$18,010$7,005.87+$315645840624138.88MIRCWF
9$26,962,198,014,878,525,000,000$26,624,456,965,410,697,000,000.00$28,216$12,979.89+$26962198014878524.00MIRCWF
10$2,154,305,968,474,146,000,000,000$2,125,456,416,598,225,800,000,000.00$51,081$27,210.54+$2154305968474146048.00MIRCWF

IRCWF vs PFE: Complete Analysis 2026

IRCWFStock

IRC Limited, an investment holding company, develops, produces, and sells industrial commodities products in the Russia, People's Republic of China, and internationally. The company operates through four segments: Mines in Production, Mines in Development, Engineering, and Other. The Mines in Production segment comprises iron ore projects in production phase, which include the Kimkan and Sutara project located in the Obluchenskoye district of the Jewish Autonomous Region in the Russian Far East. The Mines in Development segment consists of iron ore projects in the exploration and development phase comprising the Garinskoye project that focuses on iron ore deposits in the Amur region; Kostenginskoye project; and the Bolshoi Seym project that explores for ilmenomagnetite, magnetite, and ilmenite located in the located in the Tynda district of Amur region in the Russian Far East region. The Engineering segment provides technical mining research and consultancy services. The Other segment engages in the production of vanadium pentoxides and related products, and other projects. It is also involved in the provision of general trading, financing, engineering, and procurement services; and development of titanium sponge. The company was incorporated in 2010 and is headquartered in Central, Hong Kong.

Full IRCWF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IRCWF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IRCWF vs SCHDIRCWF vs JEPIIRCWF vs OIRCWF vs KOIRCWF vs MAINIRCWF vs JNJIRCWF vs MRKIRCWF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.